Chronic Sialorrhea Global Market Report 2025

The chronic sialorrhea market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of neurological disorders, population growth, greater awareness and diagnosis, and an increasing demand for non-invasive treatments.

The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $0.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to factors such as greater awareness of treatment options, a rising need for effective therapies, increased healthcare spending, growing pediatric cases, and higher demand for oral gels and liquids. Key trends expected in this period include the use of telemedicine for remote monitoring, patient-centered care models, innovations in pharmacology, the integration of speech and occupational therapies, and the development of long-acting pharmaceuticals.

The rising prevalence of neurodegenerative disorders is expected to drive the growth of the chronic sialorrhea market. Neurodegenerative disorders are a group of diseases characterized by the gradual degeneration or death of neurons in the brain and spinal cord. The increase in these disorders is influenced by factors such as genetics, family history, environmental influences, a better understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication in conditions such as Parkinson’s disease and ALS, requiring specific treatments to prevent aspiration, improve oral function, and enhance patient comfort. For example, in September 2023, Parkinson's UK reported that around 153,000 individuals in the UK are living with Parkinson's disease, and with the aging population, this number is expected to rise by 20% to an estimated 172,000 by 2030. The growing prevalence of neurodegenerative disorders will, therefore, contribute to the expansion of the chronic sialorrhea market.

Companies operating in the chronic sialorrhea market are focusing on developing innovative treatments such as oral solutions to improve patient compliance and provide non-invasive options for managing chronic sialorrhea in children, enhancing safety and reducing side effects. Oral solutions are liquid medications formulated for easy ingestion, with the active ingredient dissolved in a solvent. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. This product is available in a liquid form, making it easier to administer and ensuring accurate dosing, which is especially beneficial for pediatric patients who may have difficulty with solid medications. Sialanar offers a proven safety and efficacy profile, improving the quality of life by reducing excessive drooling, a common issue in neurodevelopmental conditions such as cerebral palsy.

In March 2022, Proveca Pharma Ltd. partnered with ExCEEd Orphan to distribute and commercialize Sialanar exclusively in Central and Eastern Europe. This collaboration aims to make Sialanar more widely available for treating chronic sialorrhea in children with neurodisabilities across eight countries in the region. The partnership addresses an unmet medical need and helps improve the quality of life for patients struggling with excessive drooling due to neurological disorders. ExCEEd Orphan S.R.O., based in the Czech Republic, specializes in helping patients with rare diseases, such as chronic sialorrhea.

Major players in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, and Solstice Neurosciences Inc.

North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic sialorrhea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic sialorrhea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic sialorrhea refers to the ongoing excessive production or inability to control saliva, commonly linked to neurological disorders such as Parkinson's disease, cerebral palsy, or ALS. Treatment options include pharmacological therapies, botulinum toxin injections, and surgical procedures aimed at improving oral function, minimizing complications, and enhancing patients' quality of life.

The primary treatment options for chronic sialorrhea are pharmacological therapies, botulinum toxin injections, surgical procedures, medical devices, and assistive therapies. Pharmacological treatments typically involve medications, such as anticholinergics and botulinum toxin injections, to reduce excessive saliva production and alleviate symptoms. These treatments can be administered in various forms, including oral medications, injections, and topical treatments. The patient population for these therapies spans both pediatric and adult groups, with key end users including hospitals, specialty clinics, rehabilitation centers, and homecare environments.

The chronic sialorrhea market research report is one of a series of new reports that provides chronic sialorrhea market statistics, including the chronic sialorrhea industry global market size, regional shares, competitors with the chronic sialorrhea market share, detailed chronic sialorrhea market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic sialorrhea industry. This chronic sialorrhea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic sialorrhea market consists of revenues earned by entities by providing services such as medical treatment services, non-surgical interventions, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic sialorrhea market also includes sales of neurostimulation devices, resection kits, absorbent clothing and bibs, and customized oral prosthetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.